BPC-157 + TB-500 Blend
How this combination works
BPC-157 and TB-500 are proposed to target soft-tissue injury through complementary but mechanistically distinct pathways. BPC-157 primarily operates via the VEGFR2/Akt-eNOS signalling axis, activating nitric oxide synthesis, ERK1/2 signalling, and growth hormone receptor upregulation to promote angiogenesis and fibroblast activity. TB-500 — the synthetic fragment of thymosin beta-4's actin-binding site — acts principally via integrin-mediated extracellular matrix remodeling, collagen deposition, and keratinocyte migration. Because these two compounds engage different upstream receptor pathways but converge on shared tissue-repair endpoints (angiogenesis, ECM remodeling, inflammation reduction), community users and some reviewers hypothesize complementary or additive benefit. This rationale is mechanistic inference; it is explicitly contradicted for Achilles tendon repair by the only published animal combination study, which found the combined group conferred no additive benefit over either agent alone — possibly reflecting convergence on shared downstream pathways. The community consensus in favour of stacking nonetheless persists and is widely discussed in r/Peptides and related forums. This rationale is therefore labelled: primarily community consensus, partially mechanistic inference, with the direct animal evidence pointing against additive benefit.
Combined mechanism
BPC-157 acts via VEGFR2 and the Akt-eNOS axis to stimulate nitric oxide production, promoting vasodilation, angiogenesis, and fibroblast activation. It also upregulates growth hormone receptor expression and reduces pro-inflammatory cytokines. Its plasma half-life is under 30 minutes in preclinical and preliminary human data, yet biological effects persist for hours to days — a mechanism not fully explained. TB-500 (Ac-LKKTETQ, residues 17–23 of thymosin beta-4) binds actin and promotes integrin-mediated ECM remodeling, collagen deposition, and endothelial cell differentiation. A metabolic study found the primary active metabolite may be Ac-LKKTE rather than the parent compound itself. Both compounds are proposed to independently stimulate angiogenesis and reduce inflammation at injured tissue sites. In the single published combination animal study — a rat Achilles tendon transection model — TB-500 at 60 µg/kg/day IP produced significantly improved biomechanical outcomes and histopathological scores, while BPC-157 showed numerical improvements without significance; the combination group showed no additive benefit compared to either agent alone, with the authors suggesting convergence on shared downstream pathways as the likely explanation. No human pharmacokinetic or pharmacodynamic data exist for the combination. The downstream tissue repair effects sought by community users (tendon, ligament, muscle recovery) would theoretically be mediated through the GH axis and cytokine modulation (BPC-157) and ECM remodeling and collagen maturation (TB-500), but the single available combination study does not support additivity in the only tested indication.
What each component does
Community dosing protocols
All protocols below are community-reported. No clinical dosing guidelines exist for this combination.
| Goal / context | BPC-157 | TB-500 | Frequency | Duration | Notes |
|---|---|---|---|---|---|
| Synergistic soft-tissue injury healing — tendon, ligament, and muscle repair commonly reported | 250 mcg subcutaneous injection (near injury site where feasible) once daily | 2.0–2.5 mg subcutaneous injection twice per week (loading phase), then once per week (maintenance) | BPC-157: once daily. TB-500: twice weekly (loading) then weekly (maintenance). | 4–6 weeks | The most widely cited BPC-157 + TB-500 stack in the community. BPC-157 is typically injected subcutaneously near the injury site; TB-500 is injected systemically. The two compounds are not co-injected in the same syringe. Community users frequently describe this as the 'gold standard' injury recovery peptide stack. The animal combination study (PMID: 42542926) found no additive benefit over either agent alone, which is not widely acknowledged in community discussions. |
| Connective tissue and joint repair post-anabolic-steroid cycle; collagen and soft-tissue recovery commonly reported | 500 mcg subcutaneous injection once daily | 2.0–2.5 mg subcutaneous injection twice per week | BPC-157: once daily. TB-500: twice weekly. | 4–6 weeks | 500 mcg/day BPC-157 is the most cited standard dose in community sources across all applications (bpc-157 approved file synth-02). Paired with the standard TB-500 loading protocol. Most commonly described in post-cycle therapy and bodybuilding recovery contexts. |
Most reported: 250–500 mcg per day (subcutaneous injection) BPC-157 + 2.0–2.5 mg, twice weekly (loading phase) TB-500 · BPC-157 daily; TB-500 twice weekly (loading) then weekly (maintenance) · 4–6 weeks
Evidence base for this combination
- Biçer O et al. Joint Diseases and Related Surgery. 2026.ANIMAL COMBINATION PMID 42542926
The only published study directly testing BPC-157 and TB-500 together. Rat Achilles tendon transection model (n=8/group). TB-500 alone significantly improved maximum load to failure and histopathological scores; BPC-157 alone showed numerical improvements without statistical significance. The combination group showed NO additive benefit compared to either agent alone. Authors suggest convergence on shared downstream pathways. Findings are limited to one animal model and one injury type.
Safety considerations for this combination
- No human combination-specific safety data exist for BPC-157 + TB-500. The only combination study used a rat model and found no additive efficacy; it did not report combination-specific adverse effects. PMID: 42542926
- TB-500 has no established human safety profile; reviewed literature states rigorous human safety data are scarce and there is potential for serious harm. BPC-157 has very limited human safety data from fewer than 30 subjects across three uncontrolled pilot studies. TB-500: PMID: 41966639. BPC-157: PMID: 42198317
- Both compounds are frequently sourced through unregulated gray-market channels. Gray-market injectable peptides carry documented risks of product contamination, manufacturing impurities, and inaccurate dosing. Pre-blended vials introduce additional uncertainty about per-component doses. PMID: 42757290 (TB-500); PMID: 40756949 (BPC-157)
- Potential for pathological angiogenesis and carcinogenesis from unregulated angiogenic peptides — a documented concern for TB-500 that applies mechanistically to any co-administered angiogenic agent including BPC-157. PMID: 42757290
- Lack of long-term safety data and systematic clinical validation for both compounds individually; no combination-specific long-term data exist at all. PMID: 42021992
Contraindications
- TB-500 is explicitly prohibited by WADA and described as a banned substance in sports in the reviewed literature. BPC-157 was temporarily banned by WADA in 2022; sport-specific professional bans may persist. Competitive athletes should verify their sport organization's current anti-doping rules before use of either compound. Inherited from TB-500 (PMID: 41476424, 26578461); Inherited from BPC-157 (PMID: 40005999)
- Neither BPC-157 nor TB-500 is approved by the FDA or any other regulatory authority for human use. Both operate in a gray market outside regulatory oversight. The combination has not been evaluated in any human clinical trial. The absence of established contraindications reflects a lack of clinical evaluation, not established safety. Inherited from BPC-157 (PMID: 42198317); Inherited from TB-500 (PMID: 41966639)
- TB-500 carries a specific risk of pathological angiogenesis and carcinogenesis from unregulated angiogenic peptides. This risk may be compounded by co-administration with BPC-157, which also promotes angiogenesis. No combination-specific cancer risk data exist; the risk is mechanistic inference. Inherited from TB-500 (PMID: 42757290); mechanistic extrapolation to combination is not directly studied
- Use in individuals with active malignancy is not studied and carries theoretical risk given both compounds promote angiogenesis. This is mechanistic inference only — no clinical data exist for either compound in oncology populations. Mechanistic inference from angiogenic mechanisms of both compounds (PMID: 40789979, 41490200)